Genetron Holdings Limited (GTH)

NASDAQ: GTH · IEX Real-Time Price · USD
1.65
+0.02 (1.23%)
At close: Jun 24, 2022 4:00 PM
1.68
+0.03 (1.82%)
After-hours: Jun 24, 2022 7:56 PM EDT
1.23%
Market Cap 149.49M
Revenue (ttm) 85.97M
Net Income (ttm) -87.17M
Shares Out 90.60M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 218,818
Open 1.69
Previous Close 1.63
Day's Range 1.63 - 1.75
52-Week Range 1.25 - 22.74
Beta 1.25
Analysts Buy
Price Target 3.84 (+132.7%)
Earnings Date Jun 2, 2022

About GTH

Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nu... [Read more...]

Industry Diagnostics & Research
IPO Date Jun 19, 2020
Employees 1,154
Stock Exchange NASDAQ
Ticker Symbol GTH
Full Company Profile

Financial Performance

In 2021, GTH's revenue was 531.95 million, an increase of 25.32% compared to the previous year's 424.49 million. Losses were -496.24 million, -83.83% less than in 2020.

Financial numbers in CNY Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for GTH stock is "Buy." The 12-month stock price forecast is 3.84, which is an increase of 132.73% from the latest price.

Price Target
$3.84
(132.73% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day

BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Receives CAP Accreditation for its Maryland Laboratory

BEIJING, June 15, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Reports Unaudited First Quarter 2022 Financial Results

BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Releases 10 New Research Results at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Receives CE Mark for FusionScan Plus Kit for Human Multi-Genes

BEIJING, June 01, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering...

Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD®

BEIJING, April 19, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offeri...

Genetron Health Presents 17 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2022

BEIJING, April 08, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offeri...

Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™'s potential in MRD Assay Developments

BEIJING, April 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offeri...

Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offeri...

Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Researc...

SAN DIEGO--(BUSINESS WIRE)-- #3Dgenomics--Arima Genomics closes $7M series B financing to support continued growth of 3D genomics portfolio for research and translational applications.

Other symbols: A

Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on M...

BEIJING, March 09, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offeri...

Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED's ORPATHYS® for NSCLC

BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health to Participate in Upcoming Investor Conferences

BEIJING, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Reiterates Full Year 2021 Revenue Guidance

BEIJING, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health's Social Contribution Campaign to Make Precision Medicine More Accessible

BEIJING, Dec. 13, 2021 (GLOBE NEWSWIRE) -- (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling test...

Why Shares of Genetron Holdings Are Up More than 9.3% on Tuesday

The Chinese biotech's third-quarter report offered some reasons for optimism.

Genetron Health Reports Third Quarter 2021 Unaudited Financial Results

BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tu...

Collaboration highlights the value of MRD solid tumor data generated by Genetron's Mutation Capsule platform, and further accelerates product development Collaboration highlights the value of MRD solid ...

Genetron Health Reveals Two Cancer Research Study Results at the Association for Molecular Pathology 2021 Annual Meeting

BEIJING, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health to Participate in the 8th BioCentury-BayHelix China Healthcare Summit

BEIJING, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health Announces Publication of Enhanced Variant Caller Performance Data in Briefings in Bioinformatics

Findings Suggest Promising Applications for UVC in Clinical NGS in Addition to Accurate Detection of Cancer Mutations Findings Suggest Promising Applications for UVC in Clinical NGS in Addition to Accur...

Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Develop...

BEIJING, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offerin...

Genetron Health's Multi-Gene Mutation Detection Kit Onco PanScan™ Obtains CE Mark

BEIJING, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecu...

Genetron Health Wins Second Prize of China's National Science and Technology Progress Award for Contributions to Lung...

BEIJING, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecu...